EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy

Luxi Yang, Jing Yang, Zhonghong Xiong, Jinsen Wei, Xiaojuan Jiang, Huili Ye, Yumin Li

Current Oncology Reports · 2026

DOI: 10.1007/s11912-026-01741-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2026. Verfasst von Luxi Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gansu Provincial Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Lipid Metabolism, Carcinoma, Hepatocellular, Carcinogenesis. Die Arbeit nennt 97 Literaturangaben. Gefördert von: Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital, International science and technology cooperation project of Gansu Provincial Science and Technology Department, The Innovation and Entrepreneurship Project for Young Talents of Lanzhou Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: Hepatocellular carcinoma (HCC), a lethal malignancy with rising global incidence, is characterized by profound metabolic reprogramming, particularly in lipid metabolism. This process, orchestrated by specialized lipid transporters and key metabolic enzymes, drives tumorigenesis, therapeutic resistance, and immune evasion. The purpose of this review is to integrate the latest mechanistic insights into how these lipid-handling proteins rewire tumor biology and reshape clinical outcomes. RECENT FINDINGS: Lipid accumulation in hepatocytes serves as a critical driver of hepatocarcinogenesis through the pathological continuum of metabolic-associated fatty liver disease (MAFLD) and steatohepatitis (MASH). These effects are mediated through coordinated pathways: the SEC63-ACLY axis enhances metastasis, FASN confers therapy resistance and immune evasion, and CD36 triggers T cell dysfunction, collectively fueling HCC progression. Notably, the novel anti-CD36 antibody PLT012 demonstrates substantial therapeutic efficacy, highlighting the clinical potential of targeting metabolic-immune crosstalk in HCC. Collectively, these findings establish the hepatic lipid metabolic network as a druggable hub and advocate for synergistic targeting strategies in HCC. This review systematically delineates the lipid transporter and key metabolic enzymes driving hepatic lipid reprogramming in HCC, integrating mechanistic and translational evidence to redefine lipid metabolism as a central therapeutic target. It further evaluates their druggability, proposing precision oncology frameworks to guide HCC treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsLipid MetabolismCarcinoma, HepatocellularCarcinogenesisHumansMetabolic ReprogrammingPrecision MedicineAnimals

Stichwörter der Autor:innen

Hepatocellular carcinomaLipid metabolismMetabolic interventionMetabolic reprogrammingTumor microenvironment

Autor:innen und Institutionen

  • Gansu Provincial Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
  • The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
  • Emergency Department, Lanzhou University Second Hospital, Lanzhou, Gansu, China. 979719610@163.com.
  • Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, Gansu, China. yehl21@lzu.edu.cn.
  • Gansu Provincial Key Laboratory of Environmental Oncology, Lanzhou University Second Hospital, Lanzhou, Gansu, China. liym_1@yeah.net.

Förderung

  • Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital
  • International science and technology cooperation project of Gansu Provincial Science and Technology Department
  • The Innovation and Entrepreneurship Project for Young Talents of Lanzhou Science and Technology Bureau
  • Science and Technology Program Project of Gansu Provincial Natural Science Foundation
  • Fundamental Research Funds for the Central Universities of Lanzhou University
  • Major Science and Technology Project of Gansu Province
  • Project of Gansu Provincial Department of Education
  • Project of Gansu Provincial Development and Reform Commission

Zitieren

APA

Yang, L., Yang, J., Xiong, Z., Wei, J., Jiang, X., Ye, H., & Li, Y. (2026). Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy. Current Oncology Reports. https://doi.org/10.1007/s11912-026-01741-2

Vancouver

Yang L, Yang J, Xiong Z, Wei J, Jiang X, Ye H, et al. Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy. Current Oncology Reports. 2026. doi:10.1007/s11912-026-01741-2

BibTeX
@article{Yang2026,
  author = {Yang, Luxi and Yang, Jing and Xiong, Zhonghong and Wei, Jinsen and Jiang, Xiaojuan and Ye, Huili and Li, Yumin},
  title = {Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy},
  journal = {Current Oncology Reports},
  year = {2026},
  doi = {10.1007/s11912-026-01741-2}
}
Kostenlos starten →